# 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct06887218/  
OnCo record `nct06887218` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of regorafenib, fluorouracil (5-FU), leucovorin (folinic acid), bevacizumab (glioblastoma use) and other drugs in colorectal cancer, run by The Methodist Hospital Research Institute, now recruiting.

## Summary

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT06887218 by The Methodist Hospital Research Institute, with a registry enrolment figure of 57 participants, started 2025-05-08 and due to reach its primary completion in 2028-12. Interventions recorded: Regorafenib (BAY 73-4506); 5FU/LV; Bevacizumab; Trifluridine-tipiracil. Conditions listed: Metastatic Colorectal Cancer (CRC). Primary outcome: Efficacy of 5FU/LV in combination with regorafenib in metastatic colorectal cancer. Colorectal eligibility wording from the registry: "Active or recent (within 3 years) non-colorectal cancer malignancies, except for low-risk, cured cancers (e". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06887218
- Phase: 2
- Setting: Randomized Phase II Trial of 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
- Sponsor: The Methodist Hospital Research Institute
- Enrolled: 57

## Sources

- ClinicalTrials.gov NCT06887218: https://clinicaltrials.gov/study/NCT06887218

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Regorafenib](https://onco.cc/drugs/regorafenib/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06887218.json